In an analysis including all reported primary end points, the hazard ratio (rosiglitazone regimens s. others) was 1.11 (95% confidence interal, 0.93 to 1.32).

• 对所有报告病例的分析中，主要终点事件风险率（罗格列酮对其它药物）为1.；11(95%25置信区间，0